<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147780</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04647</org_study_id>
    <nct_id>NCT04147780</nct_id>
  </id_info>
  <brief_title>Sentinel Node Extended in Squamous Cell Vulvar Cancer</brief_title>
  <acronym>SNEX</acronym>
  <official_title>Can the Investigators Extend the Indication for Sentinel Node Biopsy in Vulvar Cancer? A Nationwide Feasibility Study From Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diana Zach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the feasibility of sentinel node biopsy in patients&#xD;
      with squamous cell vulvar cancer, currently not regarded suitable for the sentinel node&#xD;
      technique, i.e. patients with tumors ≥4cm, multifocal tumors or locally recurrent disease. A&#xD;
      positive result of this pilot study might constitute the basis for a future full-scale&#xD;
      multinational trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      This study is primarily a pilot and feasibility trial, aiming to evaluate if sentinel node&#xD;
      biopsy has a satisfactory detection rate and negative predictive value in certain groups of&#xD;
      vulvar cancer patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      The study is planned as a prospective, multi-center cohort study in Sweden. Since 2017, the&#xD;
      treatment of vulvar cancer patients has been accredited to four tertiary referral university&#xD;
      hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping&#xD;
      University hospital, the Skåne University hospital in Lund and the Karolinska University&#xD;
      hospital in Stockholm.&#xD;
&#xD;
      Eligible patients will undergo a sentinel node biopsy additionally to their radical&#xD;
      inguinofemoral lymphadenectomy and detection rate and negative predictive value for the&#xD;
      sentinel procedure will be calculated. The study will consist of four patient groups:&#xD;
      Patients with squamous cell vulvar cancer and:&#xD;
&#xD;
        1. primary tumors ≥4cm&#xD;
&#xD;
        2. primary multifocal tumors&#xD;
&#xD;
        3. local recurrence, earlier no treatment of the groins or only sentinel node biopsy&#xD;
&#xD;
        4. local recurrence, earlier treatment of the groins with radiotherapy / inguinofemoral&#xD;
           lymphadenectomy&#xD;
&#xD;
      It is estimated to include 20-30 patients in each study group during a time frame of about 24&#xD;
      months.&#xD;
&#xD;
      RESULTS:&#xD;
&#xD;
      Results are to be expected in the end of 2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate and negative predictive value for sentinel node biopsy</measure>
    <time_frame>2019-2021</time_frame>
    <description>Calculated for each group separately. Per groin and per patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of retrieved sentinel lymph nodes</measure>
    <time_frame>2019-2021</time_frame>
    <description>Per groin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of micrometastases and isolated tumor cells, diagnosed by ultra-staging in relation to routine-histopathological examination</measure>
    <time_frame>2019-2021</time_frame>
    <description>Per groin and per patient</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vulva Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <arm_group>
    <arm_group_label>Primary vulvar cancer, tumor ≥ 4cm</arm_group_label>
    <description>Patients with primary squamous cell vulvar cancer, unifocal tumor ≥ 4cm:&#xD;
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary vulvar cancer, multifocal tumor</arm_group_label>
    <description>Patients with primary squamous cell vulvar cancer, multifocal tumor:&#xD;
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local recurrence after vulvar cancer, no earlier treatment</arm_group_label>
    <description>Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier without treatment of the groins or solely sentinel node biopsy:&#xD;
Sentinel node biopsy additional to radical inguinofemoral lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local recurrence after vulvar cancer, earlier treatment</arm_group_label>
    <description>Patients with a local recurrence of a primary squamous cell vulvar cancer, earlier treatment of the groins by lymphadenectomy and / or (chemo-)radiation:&#xD;
Sentinel node biopsy if detectable, otherwise no groin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node biopsy</intervention_name>
    <description>Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.</description>
    <arm_group_label>Local recurrence after vulvar cancer, earlier treatment</arm_group_label>
    <arm_group_label>Local recurrence after vulvar cancer, no earlier treatment</arm_group_label>
    <arm_group_label>Primary vulvar cancer, multifocal tumor</arm_group_label>
    <arm_group_label>Primary vulvar cancer, tumor ≥ 4cm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with primary squamous vulvar cancer with tumors ≥ 4cm or multifocal tumors,&#xD;
        and all patients with a local recurrence after primary squamous vulvar cancer in Sweden,&#xD;
        diagnosed during the recruitment period&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with squamous cell vulvar cancer and&#xD;
&#xD;
               1. primary tumors ≥ 4cm&#xD;
&#xD;
               2. multifocal primary tumors&#xD;
&#xD;
               3. local recurrence, earlier no treatment of the groins or only sentinel node biopsy&#xD;
&#xD;
               4. local recurrence, earlier treatment of the groins with radiotherapy /&#xD;
                  inguinofemoral lymphadenectomy&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Considered clinically appropriate for surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status &gt; 2&#xD;
&#xD;
          -  Disability to read or write in Swedish&#xD;
&#xD;
          -  Dementia / severe psychiatric illness leading to disability to understand the study /&#xD;
             study information&#xD;
&#xD;
          -  Signs of inguinal lymph node or distant metastases&#xD;
&#xD;
          -  Ongoing pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Zach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Zach, MD</last_name>
    <phone>+46851775922</phone>
    <email>diana.zach@sll.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan</state>
        <zip>17776</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Zach, MD</last_name>
      <phone>+46851775922</phone>
      <email>diana.zach@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katja Stenstrom Bohlin, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkopings University Hospital</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Preben Kjoelhede, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skanes University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Moberg, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Diana Zach</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Data excess requests will be reviewed by an external independent review panel. Requestors will be required to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

